Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susi Snitzler"'
Autor:
James B. Johnston, Trina Wang, Susi Snitzler, Harminder Paul, Sumeet Kakar, Suzanne Trudel, Deborah A. Smith, Olga Levina, Ellen N Wei, Christine Chen, Anthea Lau, Michelle Queau, Lisa W. Le
Publikováno v:
Leukemia & Lymphoma. 60:92-100
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated with combination afuresertib, a novel oral AKT
Autor:
Spencer B. Gibson, James B. Johnston, Danielle C Croucher, Barbara Sherry, Susi Snitzler, Anthea Lau, Ellen N Wei, Michelle Queau, Suzanne Trudel, David Spaner, Christine Chen, Sumeet Kakar, Lisa W. Le, Harminder Paul
Publikováno v:
Leukemialymphoma. 60(4)
Lenalidomide has anti-tumor activity in CLL but can be complicated by tumor lysis syndrome (TLS) and tumor flare (TF). In our previous study using low-dose lenalidomide in treatment-naive CLL, TLS was averted but TF remained frequent and complete res
Autor:
Christine I, Chen, Harminder, Paul, Lisa W, Le, Ellen N, Wei, Susi, Snitzler, Trina, Wang, Olga, Levina, Sumeet, Kakar, Anthea, Lau, Michelle, Queau, James B, Johnston, Deborah A, Smith, Suzanne, Trudel
Publikováno v:
Leukemialymphoma. 60(1)
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated with combination afuresertib, a novel oral AKT
Autor:
Christine I Chen, Harminder Paul, Susi Snitzler, Lisa W Le, Ellen Nong Wei, Anthea Lau, James B Johnston, Spencer B. Gibson, Michelle L. Queau, Suzanne Trudel
Publikováno v:
Blood. 126:4163-4163
Introduction: Although lenalidomide, as an immunomodulatory agent, has anti-tumor activity in CLL, its use in this disease is complicated by tumor lysis (TLS) and tumor flare (TF), especially when used frontline. From our experience using low-dose le
Autor:
Suzanne Trudel, Tong (Trina) Wang, Olga Levina, James B. Johnston, Christine Chen, Harminder Paul, Deborah A. Smith, Anthea Lau, Ellen Nong Wei, Lisa W. Le, Michelle Queau, Susi Snitzler
Publikováno v:
Blood. 126:1742-1742
Introduction: Ofatumumab is an anti-CD20 monoclonal antibody with single-agent responses of 47-58% in refractory CLL (Wierda et al 2010) and a median response duration ranging from 5.6-7.1 months. In order to improve upon these results, we combined o
Autor:
Susi Snitzler, Trina Wang, Harminder Paul, Lisa W. Le, Ellen Nong Wei, Michelle Brown, Deborah A. Smith, Christine Chen, James B. Johnston, Suzanne Trudel, Anthea Lau
Publikováno v:
Blood. 122:4175-4175
Introduction Ofatumumab is a novel anti-CD20 monoclonal antibody which led to impressive single-agent responses of 47-58% in a phase 2 study of CLL patients (pts) with refractory disease (Wierda et al 2010). Unfortunately, response durations were sho